Breast cancer, Thyroid cancer, Esophageal cancer, Gastric cancer, Colon cancer, Liver cancer, Biliary cancer, Pancreatic cancer
Conditions
Interventions
Save and analysis the sampling blood collected using a tube of 5 ml for biochemistry blood collection at the same time at the time of visit as an outpatient or admission from patients who obtained co
Sponsors
Toho Univerisity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Cases that were suspected or was diagnosed as malignant tumors clinicaly. (2)Patients who have been informed of the diagnosis as a result of malignancy. (3)Age to 20 years of age or older (4)Having a sufficient judgment capability.
Exclusion criteria
Exclusion criteria: (1)Patients who are judged inappropriate for this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor markers to be analyzed are as follows. Positive rate of each tumor marker. Analysis of correlation with clinicopathological factors and various blood concentration. -New tumor markers(cancer-specific protein and IgG antibody cancer antigen-specific antibody such as SEREX) -Existing tumor markers(p53 antibody, CEA, SCC-Ag, CYFRA21-1, AFP, CA19-9, CA125, midkine, TPA, and IAP) | — |
Countries
Japan
Contacts
Public ContactHideaki Shimada
Toho University School of Medicine Department of Surgery
Outcome results
None listed